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1 This study examines the activity of the antioxidant N-acetylcysteine on bleomycin-induced
pulmonary fibrosis in rats with emphasis on the early inflammatory phase.
2 Rats receiving N-acetylcysteine (300mg kg1 day1, intraperitoneal) had less augmented lung wet
weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in
bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score
at 3 days postbleomycin.
3 A diminished lung GSH/GSSG ratio and augmented lipid hydroperoxides were observed 3 days
postbleomycin. These changes were attenuated by N-acetylcysteine. Alveolar macrophages from
bleomycin-exposed rats released augmented amounts of superoxide anion and nitric oxide. N-
Acetylcysteine did not modify superoxide anion generation but reduced the increased production of
nitric oxide.
4 N-Acetylcysteine suppressed the bleomycin-induced increased activation of lung NF-kB (shift
assay and immunohistochemistry), and decreased the augmented levels of the early inflammatory
cytokines, tumour necrosis factor-a, interleukin-b, interleukin-6 and macrophage inflammatory
protein-2 observed in bronchoalveolar lavage fluid at 1 and 3 days postbleomycin exposure.
5 At 15 days postbleomycin, N-acetylcysteine decreased collagen deposition in bleomycin-exposed
rats (hydroxyproline content: 63517669 and 46267288 mg per lung in drug vehicle- and N-
acetylcysteine-treated rats, respectively; Po0.05). Semiquantitative histological assessment at this
stage showed less collagen deposition in N-acetylcysteine-treated rats compared to those receiving
bleomycin alone.
6 These results indicate that N-acetylcysteine reduces the primary inflammatory events, thus
preventing cellular damage and the subsequent development of pulmonary fibrosis in the bleomycin
rat model.
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Introduction
Pulmonary fibrosis is a chronic inflammatory interstitial lung
disease of potential fatal prognosis and poor response to
available medical therapy. It has been hypothesized that
activated inflammatory cells which accumulate in the lower
airways, release harmful amounts of reactive oxygen species
(ROS) that result in parenchymal injury, and interstitial and
alveolar fibrosis (Strausz et al., 1990). This oxidant burden
may be even more consequential due to a deficiency in
glutathione, a major component of the lung antioxidant
defence system (Rahman & MacNee, 2000). This pathogen-
etically relevant redox imbalance suggests that the lung
antioxidant defences may be improved with glutathione-
modulating agents like sulphydryl compounds. N-Acetylcys-
teine (NAC) is one of the most widely investigated antiox-
idants, having shown beneficial effects in various disease states
in which free radicals have been involved (Cotgreave, 1997;
Tepel et al., 2000). The results of short-term studies using oral
and intravenous NAC in patients with pulmonary fibrosis
have demonstrated its ability to improve the antioxidant screen
of the lung by elevating glutathione levels, as well as restoring
pulmonary function tests with a low incidence of adverse
effects (Meyer et al., 1994, 1995; Behr et al., 1997).
One of the clinically relevant causative agents of pulmonary
fibrosis is bleomycin, a glycopeptide antibiotic used in the*Author for correspondence; E-mail: esteban.morcillo@uv.es
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chemotherapy of different types of cancer that produces its
antineoplastic effect by causing oxidant damage to DNA (Hay
et al., 1991). Bleomycin produces pulmonary fibrosis as an
adverse effect due to the low levels in lung tissue of the cysteine
hydrolase that inactivates bleomycin; therefore, bleomycin is
widely used in experimental models to cause lung injury
leading to oxidant-induced inflammatory and fibrotic lesions
in the lung interstitium of various animal species (Hay et al.,
1991). This animal model of pulmonary fibrosis resembles that
seen in humans (Giri, 1990) and it is useful to assess the effects
of potential therapeutic agents including antioxidants (Pu-
nithavathi et al., 2000; Cortijo et al., 2001).
The present study was undertaken to evaluate the beneficial
effects of NAC in a rat model of lung injury produced by
endotracheal instillation of bleomycin with emphasis on the
changes observed at an early stage (1 and 3 days after
bleomycin exposure) when inflammatory changes predominate
by contrast with the later stage (15 days postbleomycin) where
fibrosis is evident (Lazenby et al., 1990). Morphological
changes were assessed by a semiquantitative histological score,
and lung hydroxyproline content was used as a marker of
collagen deposition. Markers of lung cell damage, airway
microvascular leakage and oxidant stress were evaluated at
this early inflammatory phase. In addition, initial events after
exposure to bleomycin are the activation of the nuclear factor
kB (NF-kB) and the release of a variety of cytokines that
modulate the inflammatory and fibroproliferative response
(Coker & Laurent, 1998; Gurujeyalakshmi et al., 2000). Key
factors of this cytokine network in bleomycin-induced
pulmonary fibrosis are the macrophage cytokines tumour
necrosis factor (TNF)-a, the interleukin (IL)-1b and IL-6
(Elias et al., 1990; Piguet, 1990; Smith et al., 1998), and the
macrophage inflammatory protein-2 (MIP-2) (Keane et al.,
1999). Therefore, we determined the effect of NAC on lung
NF-kB activation and on the levels of proinflammatory
cytokines in bronchoalveolar lavage fluid.
Methods
Materials and animals
Bleomycin sulphate, N-acetylcysteine, halothane and sodium
pentobarbital were obtained from Almirall-Prodesfarma (Bar-
celona, Spain), Zambon Group (Barcelona, Spain), Zeneca
Farma (Pontevedra, Spain) and Normon (Madrid, Spain),
respectively. Other chemicals and reagents were purchased
from standard suppliers.
Pathogen-free, male Sprague –Dawley rats, weighing 200 –
250 g at the start of experiments, were obtained from Criffa
(Iffa Credo, France). Rats were housed in a controlled
environment and fed rodent chow (A04; Panlab, Barcelona,
Spain) and tap water ad libitum. This study conformed to
European Community (Directive 86/609/EEC) and Spanish
guidelines for the use of experimental animals and it was
approved by the institutional committees of animal care and
research.
Experimental model
To produce pulmonary fibrosis, animals received endotrache-
ally, by the transoral route, a single sublethal dose of
2.5Ukg1 of bleomycin dissolved in 0.25ml saline (0.9%
NaCl). The dose of bleomycin was selected from previous
experiments in this laboratory to cause no mortality but
consistent biochemical and histological damage (Cortijo et al.,
2001). Control animals received the same volume of intra-
tracheal saline instead of bleomycin. Tracheal instillation was
carried out under halothane anaesthesia. At days 1, 3 or 15
after endotracheal bleomycin or saline, the animals were killed
by a lethal injection of sodium pentobarbital (100mg kg1,
intraperitoneal (i.p.)) followed by exsanguination from ab-
dominal aorta. Bronchoalveolar lavage was performed and
lungs were weighed and processed separately for biochemical
(immediately frozen in liquid nitrogen) and histological studies
as indicated below.
Experimental groups
Animals were randomly distributed into four experimental
groups for each time point: Group A–drug vehicle+saline;
group B –NAC+saline; group C–drug vehicle+bleomycin;
group D–NAC+bleomycin. Treatments (vehicle or NAC)
were administered i.p. on a daily basis (at 9:00 a.m.) starting 7
days prior to the intratracheal instillation of bleomycin up to
the conclusion of the experiments. The dose of NAC was
300mgkg1 body weight per day. NAC solution was made
fresh every day in sterile saline and its pH adjusted within the
range of 6.8 – 7.2 with 6n NaOH immediately before admin-
istration. NAC was given to animals in a final volume of 1ml
of vehicle. The route of administration, dose level and schedule
were based on previous studies (Giri et al., 1988; Blackwell
et al., 1996). In a group of additional experiments where lung
glutathione status was measured (see below), the same daily
dose of NAC was administered orally by gavage instead of
intraperitoneally. The oral route was selected as the usual in
the clinical setting.
Cell counts and biochemical studies in bronchoalveolar
lavage fluid
Bronchoalveolar lavage fluid (BALF) was obtained by
washing the lung four times with 5ml aliquots of saline
through a tracheal cannula. Typically, total fluid recovery
exceeded 85%, and the percentages of fluid recovered did not
significantly differ among experimental groups. The BALF
was centrifuged (300 g, 20min, 41C). The cell pellet was
resuspended for total cell count (haemocytometer) and
differential cell counts from cytospin preparations as pre-
viously outlined (Cortijo et al., 2001). The cell-free supernatant
was used for biochemical determinations. Total protein
concentration was measured by a standard dye technique
from BioRad (Munich, Germany). Lactate dehydrogenase
(LDH) activity was measured by using a commercial kit from
Boehringer Manheimm (Munich, Germany). The total amount
of TNF-a was measured by a competitive enzyme-immunoas-
say kit from Chemicon International (Temecula, CA, U.S.A.),
and the levels of TNF-a soluble receptor (type I) were
measured by a commercial solid-phase sandwich enzyme-
linked immuno-sorbent assay (ELISA) from R&D Systems
(Minneapolis, MN, U.S.A.) following the manufacturer’s
protocol. IL-1b and IL-6 concentrations were measured with
commercial ELISA kits as indicated by the manufacturer (rat
IL-1b and rat IL-6, Biotrackt, Amersham Pharmacia Biotech,
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Freiburg, Germany). MIP-2 concentration was measured with
an ELISA kit (rat MIP-2, Cytoscreent Biosource Int.,
Camarillo, CA, U.S.A.). Lipid hydroperoxide (LPO) in BALF
was measured by the Lipid Hydroperoxide Assay kit as
indicated by the manufacturer (Cayman Chemical, Ann
Arbor, MI, U.S.A.).
Biochemical assays in alveolar macrophage culture
At 3 days after bleomycin administration, groups of five rats
per group were killed according to standard ethical procedures
(see above). The lungs were then lavaged (4 5ml) with
calcium- and magnesium-free phosphate-buffered saline, pH
7.4. The pooled BALF was filtered through sterile gauze and
then centrifuged at 300 g for 10min, the erythrocytes were
lysed, and after washing three times in RPMI-1640 media, the
pelleted cells were resuspended in RPMI-1640 media contain-
ing 25mm HEPES buffer. Aliquots of the cell suspension were
counted by a haemocytometer and cell viability was measured
by trypan blue exclusion (495%). The BAL cells were
resuspended in RPMI-1640 media supplemented with 2mm
glutamine, 100Uml1 penicillin, 100mgml1 streptomycin
and 10% heat-inactivated foetal bovine serum. The cells were
seeded (1 106 cellsml1) to a 24-well tissue culture plate and
allowed to adhere for 2 h at 371C in a humidified atmosphere
in 95% O2 : 5% CO2; then, the nonadherent cells were removed
by washing three times with RPMI-1640 media. The alveolar
macrophage-enriched monolayers were incubated in fresh
RPMI-1640 media for an additional 24 h. The superoxide
anion release by alveolar macrophages was measured spectro-
photometrically using the ferricytochrome C reduction tech-
nique (Johnston, 1984). To assess nitric oxide production,
alveolar macrophages were cultured in DMEM in 96-well
plates (1 106 cellsml1) for 24 h and the accumulation of
nitrite in the culture medium was assayed using the Greiss
reaction with sodium nitrite as the standard (Closa et al.,
1999).
Biochemical studies in lung tissue
Lung hydroxyproline was determined spectrophotometrically
as previously reported (Woessner, 1961), and the results were
expressed as micrograms of hydroxyproline per lung (Shahzei-
di et al., 1991). Tissue myeloperoxidase was measured
photometrically, employing 3,30,5,50-tetramethylbenzidine as
a substrate as previously reported (Trush et al., 1994) with
some modifications (Folch et al., 1998). Reduced glutathione
(GSH) in lung tissue was measured by the GSH-transferase
method (Brigelius et al., 1983) and oxidized glutathione
(GSSG) by a method previously described in our laboratory
(Asensi et al., 1994).
Nuclear protein extraction and determination of NF-kB
binding activity by EMSA
Nuclear protein extracts were prepared from lung tissue by the
method of Deryckere & Gannon (1994). Aliquots of frozen
tissue (200 – 250mg) were mixed with liquid nitrogen and
ground to powder using a mortar and pestle. A volume of
1.5ml of solution A (0.6% Nonidet P-40, 150mm NaCl, 10mm
HEPES, pH 7.9, 1mm EDTA, 0.5mm phenylmethylsulphonyl-
fluoride (PMSF), 0.2mm benzamidine, 0.2 mgml1 pepstatin,
0.2mgml1 leupeptin and 0.2 mgml1 aprotinin) was added to
the mortar. The contents of the mortar were placed in a
Dounce tissue homogenizer (Afora, Madrid, Spain), and the
cells were lysed with five strokes of the pestle. After transfer to
a 1.5ml Eppendorf, debris was pelleted by centrifuging at
100 g for 60 s. The supernatant containing intact nuclei was
transferred to a 1.5ml Eppendorf, incubated on ice for 5min,
and centrifuged for 30 s at 17,000 g. The nuclear pellet was
resuspended in 50ml of solution B (25% glycerol, 20mm
HEPES, pH 7.9, 420mm NaCl, 1.2mm MgCl2, 0.2mm EDTA,
0.5mm dithiothreitol (DTT), 0.5mm PMSF, 2mm benzami-
dine, 2 mgml1 pepstatin, 2 mgml1 leupeptin and 2mgml1
aprotinin) and incubated on ice for 30min with occasional
vortex. The mixture was transferred to microcentrifuge tubes,
and the nuclei were pelleted by centrifugation at 17,000 g for
2min. Supernatants containing nuclear proteins were saved,
aliquoted and stored at 801C. Protein quantitation was
performed using the Bradford assay (1976).
Aliquots of nuclear extracts with equal amounts of protein
(10mg) were mixed in a total volume of 20ml with a buffer
containing 100mm HEPES (pH 7.6), 5mm EDTA, 50mm
(NH4)2SO4, 5mm DTT, 1% Tween 20, 150mm KCl, 0.1mg ml1
poly-l-Lys, and 1mg ml1 poly dI-dC according to the
manufacturer’s instructions (DIG gel shift kit from Boehringer
Mannheim and Enzo Diagnostics Inc., Germany). After
aliquots were gently mixed and equilibrated on ice for
10min, binding reactions were started by the addition of
30 fmol of double-stranded digoxygenine-labelled oligonucleo-
tide for NF-kB (the sense-strand sequence is 50-AGT TGA
GGG GAC TTT CCC AGG C-30; the underlined sequence
corresponds to a kB-binding motif) obtained from Promega
Co. (Madison, WI, U.S.A.), and allowed to proceed for 30min
at 41C. Samples were analysed on a 6% nondenaturating
polyacrylamide gel. After electrophoretical transfer to a
positively charged nylon membrane (Hybond-N+; Amersham
Pharmacia Biotech Europe GmbH, Freiburg, Germany),
complexes were visualized by a chemiluminescence detection
system (DIG gel shift kit from Boehringer Mannheim and
Enzo Diagnostics Inc., Germany). The intensity of bands was
quantified by using the image analysis system AnalySISs 3.0
(Soft Imaging System GmbH, Mu¨nster, Germany). To
ascertain the specificity of the binding reaction, competition
assays were performed in the presence of excess (100-fold, i.e.
3000 fmol) unlabelled oligonucleotide.
Histology and immunohistochemistry
For histological studies, the lung was first perfused through its
main bronchus with a fixative solution (10% neutral-buffered
formalin) at a pressure of 25 cm H2O, immersed in the fixative
for 12 – 24 h, and blocks were taken. Tissue blocks were placed
in formalin, dehydrated in a graded series of ethanol,
embedded in paraffin, cut into 4-mm-thick serial sections,
and stained with haematoxylin – eosin and Masson’s trichrome
to identify inflammatory cells, connective tissue and collagen
deposition. Histologic grading of lesions was performed by
using a blinded semiquantitative scoring system for extent and
severity of inflammation and fibrosis in lung parenchyma
based on previous studies (Greco et al., 1997) with modifica-
tions (Cortijo et al., 2001).
Prior to immunohistochemical detection of NF-kB in lung
sections, paraffin was removed and sections were boiled in
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10mm citrate buffer (pH 6) for 5min as this procedure was
found to enhance the immunoreactions. Endogenous perox-
idases were blocked with methanol –H2O2 and nonspecific
binding sites were blocked with 3% normal goat serum for 2 h.
Sections were then incubated overnight in a humidified
chamber at 41C with a rabbit polyclonal anti-p65 antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, U.S.A.)
diluted 1 : 500 for paraffin sections. This was followed by
biotinylated goat anti-rabbit antibody (Vectastain, Vector
Laboratories Inc., Burlingame, CA, U.S.A.) diluted 1 : 200 for
1 h, and the avidin – biotin complex (ABC kit, Vector) 1 : 100
for 1 h. The reaction was developed with 0.05% diaminoben-
zidine (Sigma Chemical Co., St Louis, MO, U.S.A.) and
0.03% H2O2. The specificity of the immunoreactions was
tested by incubation of the primary antibody against NF-kB
p65 with their corresponding antigenic peptide (Santa Cruz).
Statistical analysis of results
Data are expressed as means7s.e.m. of n experiments.
Statistical analysis was carried out by using a software
package (GraphPad, San Diego, CA, U.S.A.). Analysis of
variance followed by post hoc tests or nonparametric test was
applied as appropriate. A P value of less than 0.05 was
considered to be significant.
Results
Lung weight and hydroxyproline levels
Bleomycin produced a significant increase in lung weight at 3
and 15 days postexposure that was partially reduced in animals
treated with NAC (Figure 1a). Lung hydroxyproline levels, a
marker of collagen deposition, were increased approximately
two-fold at 15 days after bleomycin exposure. Treatment with
NAC significantly reduced the hydroxyproline content in
bleomycin-exposed rats although levels remained higher than
those found in animals not exposed to bleomycin (Figure 1b).
Biochemical markers of lung inflammation and damage
The pulmonary inflammatory response 3 days after bleomycin
administration was reflected by early increases of inflamma-
tory cells in BALF, tissue myeloperoxidase activity, and
LDH and proteins in BALF, thus indicating airway cell
influx, cell damage and microvascular leakage. NAC was
active to attenuate most of these early inflammatory changes
(Table 1).
As signs of acute inflammation, early increases of TNF-a,
IL-1b, IL-6 and MIP-2 levels in BALF were observed at 1 and
3 days postbleomycin (Figure 2). At 15 days postbleomycin,
only TNF-a showed increased BALF levels. The augmented
Figure 1 Lung weight/body weight (panel a) and lung hydroxypro-
line levels (panel b) in experimental groups and time points as
indicated. Treatment with N-acetylcysteine (NAC; 300mgkg1 per
day, i.p.) reduced the lung weight and the lung content of
hydroxyproline. Data are means7s.e.m. of 10 animals per group;
*Po0.05 from group A; +Po0.05 from group B.
Table 1 Effects of N-acetylcysteine (NAC) on total and differential cell counts in bronchoalveolar lavage fluid (BALF),
myeloperoxidase (MPO) activity in lung tissue, and lactate dehydrogenase (LDH) and protein in BALF measured at 3 days after
endotracheal instillation of bleomycin or saline as indicated
Group A
(drug vehicle + saline)
Group B
(NAC + saline)
Group C
(drug vehicle + bleomycin)
Group D
(NAC + bleomycin)
Total cells 0.3670.02 0.3470.05 1.7870.37* 0.8670.06*,**
Neutrophils 1.7470.71 1.9970.70 41.9778.23* 21.1673.00*,**
Eosinophils 0.1770.10 0.1670.10 4.0271.36* 3.2770.54*
Lymphocytes 1.2270.55 0.7370.23 15.8776.13* 4.3271.00*
Macrophages 33.3171.91 31.0673.86 115.84724.38* 56.8972.97*,**
MPO activity 90.478.1 91.677.7 260.4717.1* 151.6716.8*,**
LDH activity 0.4170.06 0.4470.05 0.9070.11* 0.5870.05*,**
Proteins 1.1370.18 1.1170.13 8.9670.84* 5.1070.46*,**
Total cells are expressed as  106ml1 BALF; differential cell counts are expressed as  104ml1 BALF; MPO activity as U lung1; LDH
activity as U100 g1 body weight; and protein as mg 100 g1 body weight. Data are mean7s.e.m. of five animals in each group; *Po0.05
vs group A; **Po0.05 vs group C.
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levels of these inflammatory cytokines were consistently
reduced by NAC (Figure 2).
In additional experiments carried out at 3 days postbleo-
mycin, the increased levels of TNF-a in BALF were
accompanied by an elevation of its physiologic inhibitor, the
sTNF-R; this augmentation was not affected by NAC (values
in rats receiving endotracheal saline were 1578 and 1777 pg
per lung for vehicle- and NAC-treated groups; values in
bleomycin-exposed animals were 755797 and 9037135 pg per
lung for vehicle- and NAC-treated groups; nonsignificant
between bleomycin-challenged groups; Po0.05 vs saline
groups; n¼ 5 for each group).
Glutathione status and oxidant stress markers
GSH and GSSG were measured in lung tissue at 3 days after
bleomycin exposure. A decrease in GSH accompanied by an
increase in GSSG, which translates into a decrease of the
GSH/GSSG ratio, an index of the tissue redox state, were
observed in rats instilled with bleomycin. These changes were
partially reversed in the rats treated with intraperitoneal NAC
(Table 2). Additional experiments confirmed the ability of oral
NAC to produce similar effects on lung glutathione redox
status (Table 2).
The amount of LPO in BALF was significantly increased at
3 days postbleomycin (3.470.6 nmolml1; n¼ 5) compared to
saline control (0.870.3 nmolml1; n¼ 5). Treatment with
intraperitoneal NAC did not alter the control values in
saline-challenged animals (0.970.3; n¼ 3) but attenuated the
levels detected in bleomycin-exposed rats (1.770.4 nmolml1;
n¼ 5, Po0.05 compared to drug vehicle+bleomycin).
The production of superoxide anion and nitric oxide by
alveolar macrophages at 3 days postchallenge was higher in
bleomycin-exposed rats compared to saline controls, thus
indicating the presence of oxidative and nitrosative stress in
this model. The generation of superoxide anion by alveolar
macrophages was not diminished by NAC but a slight, albeit
significant, reduction of nitrite production was detected
(Figure 3).
Nuclear factor-kB binding activity and immunostaining
NF-kB binding activity determined by shift assay was
increased in nuclear extracts from lungs obtained at 1, 3 and
15 days postbleomycin challenge compared to saline control
animals. This augmentation of NF-kB activity was suppressed
in NAC-treated rats (Figure 4).
Lung sections from vehicle+vehicle rats showed a small
degree of immunostaining for NF-kB at 3 days postbleomycin
exposure, while an intense nuclear staining was noticed in
airway epithelial cells, macrophages and other inflammatory
cells (Figure 5). The immunostaining for NF-kB was
diminished in NAC-treated rats (Figure 5).
Histopathology
Lungs from rats in groups A (drug vehicle+saline) and B
(NAC+saline) were histologically normal (not shown). Lungs
Figure 2 Time-course changes in the levels of tumour necrosis factor (TNF)-a, IL-1b, IL-6 and MIP-2 in bronchoalveolar lavage
fluid (BALF) at 1, 3 and 15 days postbleomycin or saline in experimental groups as indicated. Treatment with N-acetylcysteine
(NAC; 300mgkg1 per day, i.p.) reduced the augmented levels of inflammatory cytokines in bleomycin-exposed rats. Data are
means7s.e.m. of four to seven animals; *Po0.05 from group A; +Po0.05 from group C.
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from rats in group C (drug vehicle+bleomycin), killed at 3
days postbleomycin, showed extensive areas of oedema,
congestion of alveolar walls and a moderate alveolar exudate
composed mainly of polymorphonuclear leukocytes. Within
the alveolar interstitium, an accumulation of polymorpho-
nuclear neutrophils and scattered lymphocytes and macro-
phages was observed (Figure 6a). These areas were randomly
distributed throughout the pulmonary parenchyma. No signs
of fibrotic lesions were observed. Pulmonary lesions in group
D (NAC+bleomycin) at 3 days postbleomycin were similar to
those described for group C (Figure 6b) but better histological
scores were obtained (Table 3).
The pulmonary lesions observed at 15 days postbleomycin
in group C consisted of multifocal areas of severe inflamma-
tion and intense fibrosis (Figure 6c,d). In these areas, an
intense thickening of alveolar septa with evident infiltration of
macrophages, lymphocytes, polymorphonuclear neutrophils
and some eosinophils was observed. Masson-trichrome stain-
ing confirmed the presence of an intense fibrosis in the
inflammatory focal areas (Figure 6f). In contrast, NAC-
treated animals at 15 days postbleomycin (group D) showed a
less severe pattern of pulmonary lesion, consisting of multi-
focal areas of moderate inflammation and slight fibrosis
(Figure 6e; Table 3). Although the type of inflammatory
infiltrate was similar to that observed in group C, the
pulmonary parenchyma was less affected. The reduced
intensity of the fibrosis was confirmed by Masson-trichrome
staining (Figure 6g).
Discussion
The results of the present study indicate that pretreatment with
NAC was effective in reducing lung damage produced by
intratracheal instillation of bleomycin in rats. This beneficial
effect was based on the improvement of early inflammatory
changes following endotracheal bleomycin as well as on the
diminished accumulation of collagen and betterment of
histologic lesion scores. This finding adds to a substantial
amount of previous work showing the activity of NAC, either
systemically (intraperitoneal or oral) or locally (aerosolized or
endotracheal) administered, to prevent lung damage and
subsequent fibrosis in rats and mice (Berend, 1985; Jamieson
et al., 1987; Shahzeidi et al., 1991; Hagiwara et al., 2000;
Cortijo et al., 2001). Yet, Ward et al. (1987) reported that
subcutaneous NAC failed to ameliorate bleomycin-induced
lung toxicity in rat, and Giri et al. (1988) found that
intraperitoneal NAC did not reduce the lung damage in
hamsters. Similarly, the activity of other antioxidants against
pulmonary fibrosis produced by bleomycin has been recently
demonstrated (Gurujeyalakshmi et al., 2000; Punithavathi
et al., 2000; Tamagawa et al., 2000). The effectiveness of NAC
in this experimental model would be consistent with the
beneficial effect shown for this thiol compound in patients with
idiopathic pulmonary fibrosis (Meyer et al., 1994, 1995; Behr
et al., 1997).
The mechanism through which NAC could limit fibrosis is
still uncertain, but is likely to be related to its ability to reduce
damage to lung structures in the early inflammatory stage of
the disease process. The pulmonary injury produced by
bleomycin involves, as an initial event, the generation of
oxidant species by an iron-dependent mechanism (Hay et al.,
1991). Further damage is probably elicited by increased
amounts of ROS produced by activated inflammatory cells,
which accumulate in the bleomycin-induced pulmonary lesions
(Strausz et al., 1990; MacNee & Rahman, 1995). In this
scenario, two potential mechanisms for this lower degree of
lesion would be possible. Either NAC reduces the ROS
production or the ROS-induced aggression, leading to the
Table 2 Effect of N-acetylcysteine (NAC) on the glutathione content of rat lung tissue at 3 days postsaline or bleomycin exposure
(NAC was daily administered at the same dose level (300mgkg1) by intraperitoneal (i.p.) or oral route)
GSH (mmol g1 lung tissue) GSSG (nmol g1 lung tissue) GSH/GSSG ratio
Drug vehicle+saline 2.2270.12 22.1972.49 103.7078.70
NAC (i.p.)+saline 1.9870.21 24.9773.16 83.27715.22
Drug vehicle+bleomycin 1.7570.12* 44.7776.94* 41.2273.90*
NAC (i.p.)+bleomycin 1.8170.11 25.9071.65** 71.8678.45*,**
Drug vehicle+saline 2.0770.14 27.8873.59 78.89710.00
NAC (oral)+saline 2.1070.12 27.9772.78 77.08710.29
Drug vehicle+bleomycin 1.6170.12* 45.6273.20* 36.0673.71*
NAC (oral)+bleomycin 1.7070.19 32.0672.62** 53.976.31**
Values are expressed as mean7s.e.m. of five animals in each group except four in ‘NAC (i.p.) + saline’ and three in ‘NAC (oral) + saline’;
*Po0.05 from the corresponding ‘drug vehicle+saline’; **Po0.05 from the corresponding ‘drug vehicle+bleomycin’.
Figure 3 Effect of N-acetylcysteine (NAC; 300mgkg1 per day,
i.p.) on alveolar macrophage release of superoxide anion and nitrite
in the culture medium. NAC did not significantly change superoxide
anion release but attenuated nitric oxide production. Data are
means7s.e.m. of five independent observations in each group.
*Po0.05 from group A; +Po0.05 from group C.
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early inflammatory phase. Our results would be in favour of a
combination of effects at this early stage of the process. Thus,
in the acute stage of the lesion (3 days), NAC attenuated
bleomycin-induced exudation and cell damage (protein and
LDH levels in BALF) as well as decreased the severity of the
inflammatory infiltrate (myeloperoxidase activity, differential
cell counts and histologic scores) and the oxidant stress burden
(see below). NAC has demonstrated antiexudative effects in
the airways in vivo (Bernareggi et al., 1999), as well as a
capacity to inhibit the expression of redox-sensitive cell
adhesion molecules in vitro (Faruqi et al., 1997) and in vivo
(Alvarez & Sanz, 2001; Cuzzocrea et al., 2001). In particular,
NAC has been demonstrated to suppress the early upregula-
tion of P-selectin in bleomycin-induced lung injury in rats
(Serrano-Mollar et al., 2002).
The fact that these events have been observed in the early
inflammatory phase, in which fibrosis-related biochemical and
histological changes are still imperceptible, suggests that the
effect of NAC may be related to tissue preservation, that is, a
decreased extent of lung lesion at the initial phase in NAC-
treated animals would imply a reduced fibrotic process at later
stages. This hypothesis does not exclude a direct effect of NAC
on fibrogenesis since it has been reported that NAC inhibits
fibroblast proliferation in vitro (Cantin et al., 1990).
NAC may act directly as an oxygen radical scavenger
(Aruoma et al., 1989) but also, since it is a cell-permeable
sulphydryl compound, readily enters cells and could promote
the production of GSH by furnishing its limiting precursor, l-
cysteine (Cotgreave, 1997). Both mechanisms may account for
providing protection against bleomycin- and leukocyte-
mediated cytotoxicity in the lung. The glutathione status has
been studied in patients with idiopathic pulmonary fibrosis.
Meyer et al. (1994, 1995) reported a deficiency in total
glutathione levels in epithelial lining fluid but not in BALF
from these patients. Oral treatment with NAC increased the
total glutathione levels in epithelial lining and BALF of
patients with idiopathic pulmonary fibrosis accompanied by
an improvement of pulmonary function tests (Meyer et al.,
1994; Behr et al., 1997). In the present study, we found a
decrease of GSH accompanied by an increase of GSSG levels
in lung tissue which translates into lower GSH/GSSG ratios at
3 days after exposure to bleomycin, thus confirming the early
oxidative stress present in this model.
At the same time, the amount of LPO in BALF was
increased, and alveolar macrophages release larger amounts of
superoxide anion and nitric oxide, which is in keeping with the
findings of other studies (Yamazaki et al., 1998; Hagiwara
et al., 2000; Punithavathi et al., 2000), and indicates the
existence of an important oxidant burden imposed on
pulmonary tissues. NAC (oral or i.p.) did not significantly
change the GSH levels but partly diminished levels of GSSG,
thus increasing the GSH/GSSG ratio, which indicates an
attenuation of oxidant stress. Giri et al. (1988) also reported
that NAC (200mg kg1 per day for 13 days; i.p.) improved the
lung glutathione redox state in bleomycin-exposed hamsters,
and we also found higher glutathione levels in BALF of
bleomycin-exposed rats orally treated with NAC (Cortijo et al.,
2001). NAC did not inhibit the superoxide anion release by
alveolar macrophages but the amount of nitric oxide was
decreased. The capacity of NAC to decrease nitric oxide
production in rat macrophages has been previously demon-
strated (Pahan et al., 1998; Cuzzocrea et al., 2001). Taken
together, these data indicate that NAC is endowed with direct
and indirect antioxidant properties, which result in a beneficial
effect against the oxidant-induced pulmonary damage elicited
by bleomycin.
Another target for ROS generated by bleomycin is the
activation of NF-kB, a transcription factor that regulates
many cytokine genes, including those examined in this study,
TNF-a, IL-1b and IL-6, and MIP-2 (Pahl, 1999). TNF-a and
IL-1b may in turn also activate NF-kB (Barnes & Karin,
1997). Bleomycin augmented the NF-kB binding activity
assessed as shift assay at 1, 3 and 15 days postexposure, a
Figure 4 Effect of N-acetylcysteine (NAC; 300mg kg1 per day,
i.p.) on the bleomycin-induced increase of NF-kB-binding activity
assessed at 1, 3 and 15 days postexposure. Panel (a) An
electrophoretic gel mobility shift assay showing NF-kB-binding
activity in rat lung cell nuclear proteins from individual animals at 1
day postbleomycin. Lane 1: Free probe. Lanes 2, 3, 4 and 5
correspond to experimental groups A (drug vehicle + saline), B
(NAC + saline), C (drug vehicle + bleomycin) and D (NAC +
bleomycin), respectively. The specificity of the binding was
confirmed by adding excess unlabelled NF-kB oligonucleotide (lane
6). Panel (b) The densitometric scanning of the band shift data of
NF-kB-binding activity is expressed as relative values compared to
their corresponding values in group A taken as unity. There was a
significant increase in NF-kB-binding activity that was suppressed in
NAC-treated rats. Columns are means7s.e.m. of three to four
independent experiments for each group. *Po0.05 compared to
group A; +Po0.05 from group B.
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Figure 5 Immunohistochemical analysis of NF-kB in lung sections obtained at 3 days postbleomycin or saline exposure in vehicle-
or N-acetylcysteine (NAC, 300mgkg1 per day, i.p.)-treated rats. Lung sections were obtained from control rats (vehicle+vehicle;
(a, b)), and from rats exposed to bleomycin and receiving drug vehicle (c, d) or NAC (e, f). Panels show sections stained with anti-
p65 antibody followed by the avidin – biotin complex. The immunohistochemical localization of NF-kB appears as dark-brown
positive nuclear staining in airway epithelial cells as well as macrophages and other inflammatory cells like polymorphonuclear
leukocytes in interalveolar septa. There is a low staining level in control lungs. Note the high level of staining in the epithelium of
bleomycin-exposed rats (panel (d) compared to the virtual absence in epithelial cells from control animals (panel (b). The increased
expression of p65 in vehicle+bleomycin rats was markedly diminished in NAC+bleomycin samples (cf. (c,d) and (e,f)). Original
magnification  25 (a, c, e) and  40 (b, d, f).
Table 3 Histologic lesion scores of lungs from rats receiving endotracheal bleomycin (BL) in the absence (group C) and presence of
treatment with N-acetylcysteine (NAC; group D)
Inflammation Fibrosis
Severity Extension Severity Extension
3 days postexposure
Drug vehicle+bleomycin 2.4070.24 2.2070.20 Nil Nil
NAC+bleomycin 1.8070.20* 1.6070.24* Nil Nil
15 days postexposure
Drug vehicle+bleomycin 2.00+0.32 2.2070.37 2.4070.24 2.8070.20
NAC+bleomycin 1.6770.21 1.8370.17 1.5070.22* 2.0070.26*
Lung sections from bleomycin-injured rats were coded and then blindly scored for inflammation and fibrosis. Lung inflammation was
scored in tissue sections stained with haematoxylin and eosin on a scale of 0 – 4. Lung fibrosis was scored in trichrome-stained sections on
a scale of 0 – 4. Data are means7s.e.m. of five to six animals per group. *Po0.05 from the corresponding group exposed to bleomycin
without NAC.
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finding consistent with results from the mouse model
(Gurujeyalakshmi et al., 2000). This sustained activation
suggests a crucial role of this transcription factor in the
sequential expression of pathogenetically relevant mediators of
inflammation and fibrosis in this experimental model. The
relevance of this target has been demonstrated with antisense
oligonucleotides to NF-kB that ameliorate bleomycin-induced
lung fibrosis in mice (Zhang et al., 2000). The immunohisto-
chemical detection of NF-kB at 3 days postbleomycin indicates
a small degree of immunostaining in control preparations
(Figure 5), a finding consistent with the existence of
constitutive NF-kB levels in alveolar macrophages from
normal lung (Farver et al., 1998). Bleomycin exposure
augmented the immunostaining for NF-kB in different cell
types including airway epithelial cells, alveolar macrophages
and polymorphonuclear cells in interalveolar septa. Staining
for NF-kB in airway epithelium and inflammatory cells has
also been reported in other inflammatory lung diseases (Hart
et al., 1998).
We found that NAC suppressed this activation of NF-kB
assessed as shift assay and immunostaining, and therefore this
blocking effect may be crucial for reducing the upregulation of
proinflammatory and fibrogenic cytokine genes in the bleo-
mycin model of lung fibrosis. This finding would be consistent
with the report by Blackwell et al. (1996) that NAC (200mg
kg1, i.p.) blocks NF-kB activation in lung tissue in the acute
lung injury produced by lipopolysaccharide, and also with
findings in other in vivo animal models of oxidant stress (Ho
et al., 1999; Cuzzocrea et al., 2001). Blocking of the activation
of NF-kB has also been suggested to be the mechanism of the
antifibrotic effect of other antioxidants in the bleomycin model
(Gurujeyalakshmi et al., 2000).
TNF-a is an inflammatory cytokine secreted by activated
alveolar macrophages that has been strongly implicated in the
Figure 6 Representative photomicrographs of lung histopathology in groups B (vehicle + bleomycin) and C (N-acetylcysteine
(NAC)+ bleomycin) at 3 days (a) and (b), respectively) and 15 days (c, d) and (e), respectively) following endotracheal bleomycin.
Lung sections were stained with haematoxylin – eosin. NAC dose was of 300mgkg1 per day given intraperitoneally. Normal lungs
observed for group A (vehicle + vehicle) are not shown. Three days after intratracheal bleomycin, a marked peribronchial
interstitial infiltration of inflammatory cells and alveolar oedema were patent in vehicle-treated animals (a). These pulmonary
lesions were not improved by NAC (b). At 15 days postbleomycin, inflammation and fibrosis were present in vehicle-treated rats
((c,d)), but NAC ameliorated the pulmonary lesions (e). Panels (f) (group B) and (g) (group C) show lung sections stained with
Masson-trichrome at 15 days postbleomycin. The presence of interstitial collagen was diminished by NAC. Original magnification
of panels  10 (except (d)  20).
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pathogenesis of pulmonary fibrosis and considered a potential
target for therapeutic interventions (Piguet, 1990; Zhang et al.,
1993; Smith et al., 1998; Ishii et al., 2000). In the present study,
we confirmed that bleomycin exposure increased TNF-a levels
in BALF both at early (1 – 3 days) and late (15 days) stages of
the process initiated after bleomycin exposure. In addition,
increased levels of its physiologic inhibitor, sTNF-R, were also
found at the time point studied (3 days). Augmented levels of
sTNF-R have been reported for other inflammatory lung
diseases in which it may influence the local bioactivity of TNF-
a (Suter et al., 1992; Hino et al., 1997). Our results show that
NAC remarkably reduced the augmented levels of TNF-a in
BALF without affecting those of sTNF-R. This result is
consistent with decreases of elevated TNF-a levels recently
reported for other antioxidants in the bleomycin model of
pulmonary fibrosis and may be related to its blocking effect on
the activation of NF-kB (Gurujeyalakshmi et al., 2000;
Punithavathi et al., 2000). This inhibitory effect on TNF-a
production may certainly contribute to the beneficial effect of
these antioxidants including NAC against bleomycin-induced
lung fibrosis.
Recent work demonstrates that IL-1b induces acute lung
inflammation that converts to pulmonary fibrosis, and this
cytokine is considered a valid target for therapeutic interven-
tion in this disease (Kolb et al., 2001). TNF-a has been shown
to stimulate IL-1b secretion in human alveolar macrophages
(Scheule et al., 1992), and in turn IL-1b increases the
expression of TNF-a and IL-6 (Kolb et al., 2001). IL-6
released from alveolar macrophages has also been implicated
in the pathogenesis of human and experimental pulmonary
fibrosis (Elias et al., 1990). We found augmented BALF levels
of IL-b and IL-6 at the early inflammatory phase (1 – 3 days
postbleomycin) but not at the fibrotic phase (15 days after
bleomycin), which is consistent with the transient expression of
these macrophage cytokines and confirms the findings in a
bleomycin mouse model (Gurujeyalakshmi et al., 2000). Rats
treated with NAC showed lower levels of IL-1b and IL-6 in
BALF (this study), a finding consistent with the demonstrated
ability of NAC to inhibit IL-1b release in carrageenan-induced
pleuresy (Cuzzocrea et al., 2001) and IL-6 in lung epithelial
cells (Simeonova et al., 1997). This inhibitory activity of NAC
may contribute to its beneficial effect in this experimental
model.
Another inflammatory cytokine relevant to the bleomycin
model is the CXC chemokine MIP-2, a murine functional
homologue of interleukin-8 that may also be regulated by NF-
kB (Barnes & Karin, 1997; Keane et al., 1999). Recent studies
indicate the importance of MIP-2 as a possible chemoattrac-
tant factor for neutrophils (Hagiwara et al., 2000) but also
involved in the angiogenesis and fibrotic process (Keane et al.,
1999). NAC diminished the elevated MIP-2 levels, and this
effect may also contribute to the effectiveness of NAC in the
bleomycin model of lung fibrosis.
NAC has also been reported in in vitro studies to interfere
with other inflammatory mediators involved in lung fibrogen-
esis (Galis et al., 1998; Gon et al., 2000), but the influence of
these mechanisms on the effects of NAC on bleomycin-
induced lung fibrosis remains to be investigated. Under the
conditions of the present study, the results obtained suggest
that, in the acute phase of inflammation, NAC has a protective
effect by acting as an antioxidant. Additional studies are
required to specify further the main mechanism(s) of the
beneficial effect of NAC in this model as well as the potential
for NAC administration as a concomitant therapy for patients
with fibrosing alveolitis, including that produced during
bleomycin treatment.
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